Addition of atezolizumab to nab-paclitaxel plus carboplatin is a new standard option for the first-line treatment for non-squamous non-small cell lung cancer

被引：1
|
作者：
Yamaguchi, Teppei [1 ]
Hida, Toyoaki [1 ]
机构：
[1] Aichi Canc Ctr Hosp, Dept Thorac Oncol, Nagoya, Aichi, Japan
来源：
TRANSLATIONAL CANCER RESEARCH | 2019年 / 8卷 / 08期
关键词：
PHASE-III; MAINTENANCE BEVACIZUMAB; CHEMOTHERAPY; COMBINATION; NIVOLUMAB; DOCETAXEL; EFFICACY; THERAPY; SAFETY;
D O I：
10.21037/tcr.2019.12.57
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E11 / E14
页数：4
相关论文
共 50 条
  • [21] Nab-Paclitaxel in combination with Cisplatin Versus Docetaxel Plus Cisplatin as First-Line Therapy in Non-small Cell Lung Cancer
    Yi Chen
    Jinyu Li
    Shixue Chen
    Yibao Zhang
    Yi Hu
    Guoqing Zhang
    Xiang Yan
    Shunchang Jiao
    Scientific Reports, 7
  • [22] PEMETREXED AND CARBOPLATIN VERSUS DOCETAXEL AND CARBOPLATIN AS FIRST-LINE TREATMENT FOR PATIENTS WITH ADVANCED, NON-SQUAMOUS, NON-SMALL CELL LUNG CANCER (NSCLC)
    Ganju, Vinod
    Pereira, Jose
    Kim, Joo-Hang
    Magallanes, Manuel
    Lee, Dae-Ho
    Wang, Jie
    Martinez, Luis
    Barraclough, Helen
    Van Kooten, Maximiliano
    Orlando, Mauro
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S417 - S418
  • [23] Efficacy and safety of weekly nab-paclitaxel plus carboplatin advanced non-small cell lung cancer
    Satouchi, Miyako
    Okamoto, Isamu
    Sakai, Hiroshi
    Yamamoto, Nobuyuki
    Ichinose, Yukito
    Ohmatsu, Hironobu
    Nogami, Naoyuki
    Takeda, Koji
    Mitsudomi, Tetsuya
    Kasahara, Kazuo
    Negoro, Shunichi
    LUNG CANCER, 2013, 81 (01) : 97 - 101
  • [24] Utility of atezolizumab plus bevacizumab, carboplatin, and paclitaxel combination for the treatment of advanced non-squamous non-small cell lung cancer patients with malignant pleural effusion
    Hisakane, Kakeru
    Atsumi, Kenichiro
    Seike, Masahiro
    Hirose, Takashi
    TRANSLATIONAL LUNG CANCER RESEARCH, 2024, 13 (09)
  • [25] PHASE II STUDY OF BEVACIZUMAB IN COMBINATION WITH CARBOPLATIN PLUS PACLITAXEL AS FIRST-LINE CHEMOTHERAPY FOR NON-SQUAMOUS NON-SMALL CELL LUNG CANCER WITH MALIGNANT PLEURAL EFFUSION
    Tamiya, Akihiro
    Tamiya, Motohiro
    Yamadori, Tadahiro
    Yasue, Tomomi
    Nakao, Keiko
    Shiroyama, Takayuki
    Asami, Kazuhiro
    Morishita, Naoko
    Suzuki, Hidekazu
    Okamoto, Norio
    Okishio, Kyoichi
    Kawaguchi, Tomoya
    Hirashima, Tomonori
    Atagi, Shinji
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S1159 - S1160
  • [26] Phase II study of bevacizumab in combination with carboplatin plus paclitaxel as first-line chemotherapy for non-squamous non-small cell lung cancer with malignant pleural effusion
    Tamiya, M.
    Tamiya, A.
    Asami, K.
    Okishio, K.
    Kawagchi, T.
    Suzuki, H.
    Okamoto, N.
    Kawase, I.
    Atagi, S.
    Hirashima, T.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S826 - S826
  • [27] The cost effectiveness of penpulimab with paclitaxel and carboplatin in first-line treatment of metastatic squamous non-small cell lung cancer
    Kaiqi Zhu
    Zhaoyi Pan
    Mengyao Qin
    Jin Huang
    Scientific Reports, 15 (1)
  • [28] Biosimilar candidate IBI305 plus paclitaxel/carboplatin for the treatment of non-squamous non-small cell lung cancer
    Yang, Yunpeng
    Wu, Bin
    Huang, Linian
    Shi, Meiqi
    Liu, Yunpeng
    Zhao, Yanqiu
    Wang, Lijun
    Lu, Shun
    Chen, Gongyan
    Li, Baolan
    Xie, Conghua
    Fang, Jian
    Yang, Nong
    Zhang, Yiping
    Cui, Jiuwei
    Song, Yong
    Zhang, Cuiying
    Mei, Xiaodong
    Cao, Bangwei
    Yang, Lan
    Cheng, Ying
    Ying, Kejing
    Sun, Tao
    Ren, Biyong
    Yu, Qitao
    Liao, Zijun
    Pei, Zhidong
    Wang, Mengzhao
    Zhou, Jianying
    Yu, Shiying
    Feng, Guosheng
    Wan, Huiping
    Wang, Huaqing
    Gao, Shegan
    Wang, Jinliang
    An, Guangyu
    Geng, Yi
    Ji, Yanxia
    Yuan, Ying
    Ma, Shenglin
    Jia, Zhongyao
    Hu, Mu
    Zhou, Hui
    Yu, Jie
    Sun, Xing
    Zhang, Li
    TRANSLATIONAL LUNG CANCER RESEARCH, 2019, 8 (06) : 989 - +
  • [29] NAB-PACLITAXEL IN COMBINATION WITH CARBOPLATIN AS FIRST-LINE THERAPY IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): ANALYSIS OF PREDICTIVE FACTORS
    Hirsh, Vera
    Page, Ray
    Ko, Amy
    Renschler, Markus F.
    Socinski, Mark A.
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S879 - S879
  • [30] COST EFFECTIVENESS OF BEVACIZUMAB ADDITION TO THE FIRST LINE OF CARBOPLATIN plus PACLITAXEL CHEMOTHERAPY IN PATIENTS WITH NON-SQUAMOUS NON-SMALL CELL LUNG CANCER WITH ECOG BETWEEN 0 AND 1
    Parody, E.
    Guevara, C. A.
    Aguirre, A. F.
    VALUE IN HEALTH, 2015, 18 (07) : A822 - A822
12345